戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed catagen development (effluvium, alopecia, hirsutism).
2  themselves and were rated by clinicians for hirsutism.
3 isability (DD/ID), abnormal extremities, and hirsutism.
4 gy in these women, such as oligomenorrhea or hirsutism.
5 to tacrolimus, two for rejection and one for hirsutism.
6  as cancers of steroid-sensitive tissues and hirsutism.
7 ence among diverse individuals with PCOS and hirsutism.
8 s younger individuals and those with acne or hirsutism.
9  ovarian androgens to insulin resistance and hirsutism.
10 ne, hidradenitis, androgenetic alopecia, and hirsutism.
11 icacy and fewest adverse events for treating hirsutism?
12       Among women with PCOS, the presence of hirsutism (43.9% [54 of 123] vs 30.9% [34 of 110], P = .
13 men who met the criteria had higher rates of hirsutism (53.3% [144 of 270] vs 31.2% [15 of 48], P = .
14                                              Hirsutism (94%) and gingival hyperplasia (51%) occurred
15 with menstrual irregularities, subfertility, hirsutism, acne, and a range of endocrine abnormalities,
16    We also highlight other issues, including hirsutism, acne, pregnancy, and neonatal outcome, that r
17                                              Hirsutism and AN are the most reliable cutaneous markers
18                                When present, hirsutism and AN should raise clinical concern that warr
19 OS criteria demonstrated more severe truncal hirsutism and higher rates of axillary AN.
20 atypical genitalia, to adult presentation of hirsutism and irregular menses.
21  manifestations, mainly represented by acne, hirsutism, and alopecia.
22 many skin conditions, such as acne vulgaris, hirsutism, and androgenic alopecia.
23 mprovement in hypertension, gum hyperplasia, hirsutism, and cushingoid appearance.
24 ental delay, characteristic facial features, hirsutism, and hand and feet anomalies, with the first p
25 nd other sex hormones), menstrual frequency, hirsutism, and PCOS-related quality of life (QoL).
26 ome (PCOS) diagnosed after irregular menses, hirsutism, and polycystic ovaries, is concerned about we
27  ophthalmologic and genitourinary anomalies; hirsutism; and characteristic facial features.
28                   Quality-of-life impacts of hirsutism are consistent with that reported for other se
29 patients and clinicians; patients view their hirsutism as more severe than clinicians do.
30 ve been associated with improvement for mild hirsutism, as has flutamide (250 mg) twice daily and spi
31  to treat multiple human diseases, including hirsutism, benign prostatic hypertrophy, and prostate ca
32  is notable discordance in the perception of hirsutism between patients and clinicians; patients view
33 l dysmorphia, upper-extremity malformations, hirsutism, cardiac defects, growth and cognitive retarda
34         Insulin resistance, infertility, and hirsutism, common characteristics of polycystic ovary sy
35                            Higher degrees of hirsutism (determined by both patients and clinicians) w
36  patients reported immunosuppression-induced hirsutism, gingival hyperplasia, acne, alopecia, or cush
37                                              Hirsutism had a significant negative effect on quality o
38 sulin resistance (ie, cortisol and insulin), hirsutism [ie, dehydroepiandosterone (DHEA) and androste
39 d Ferriman-Gallwey score (FGS) (a measure of hirsutism in females) were recorded.
40 aser and light-based therapies in addressing hirsutism in women with PCOS.
41           Qualitative evidence suggests that hirsutism inflicts significant negative impacts on quali
42 olescents and young women often present with hirsutism, irregular menses, and obesity.
43 re (IRT)-based methods for cotton (Gossypium hirsutism L.) water stress detection using in-field sens
44 y and is associated with polycystic ovaries, hirsutism, obesity, and insulin resistance.
45 ects such as gingival hyperplasia and facial hirsutism on physical appearance.
46 ting androgenic skin disorders such as acne, hirsutism, or androgenetic alopecia remains to be establ
47  no reports of hyperglycaemia, hypertension, hirsutism, or Cushingoid appearance in any of the treatm
48  (pooled proportion, 18%; 95% CI, 4-31), and hirsutism (pooled proportion, 14%; 95% CI, 6-21).
49 or statistically significant improvements in hirsutism, QoL, or other sex hormones, which may be due
50                                              Hirsutism-related quality of life was assessed using the
51                                              Hirsutism represents a significant concern for women wit
52 ser demonstrated significant improvements in hirsutism severity and psychological outcomes, particula
53      Clinicians and patients rated degree of hirsutism using the modified Ferriman-Gallwey (mFG) inst
54 erse events (AEs) for Cushingoid appearance, hirsutism, weight gain, and behavior change were less fo
55 r or light-based hair reduction therapies on hirsutism were abstracted.
56 tients was 8.63 (P < .001); self-ratings for hirsutism were higher for all body areas except thigh.
57              However, most cases of acne and hirsutism were mild and did not require withdrawal from
58                                     Acne and hirsutism were reported in 33% and 16%, respectively, of
59                         Only self-ratings of hirsutism were significantly associated with risk of dep
60 only partially associated with the degree of hirsutism, with self-ratings being more highly associate